ANIXA BIOSCIENCES, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ANIXA BIOSCIENCES, INC. stock issued during period, value, new issues for the quarter ending 2026-07-31 was $1.94M, a 0.41% increase year-over-year.
- ANIXA BIOSCIENCES, INC. stock issued during period, value, new issues for the quarter ending 2026-04-30 was $1.25M, a 8792.86% increase year-over-year.
- ANIXA BIOSCIENCES, INC. stock issued during period, value, new issues for the quarter ending 2026-01-31 was $1.63M.
- ANIXA BIOSCIENCES, INC. stock issued during period, value, new issues for the quarter ending 2025-10-31 was $454.00K.
- ANIXA BIOSCIENCES, INC. stock issued during period, value, new issues for fiscal 2025 was $2.38M, a 19.53% decline from fiscal 2024.
- ANIXA BIOSCIENCES, INC. stock issued during period, value, new issues for fiscal 2024 was $2.96M.
- ANIXA BIOSCIENCES, INC. stock issued during period, value, new issues for fiscal 2022 was $100.00M, a 823.02% increase from fiscal 2021.
- ANIXA BIOSCIENCES, INC. stock issued during period, value, new issues for fiscal 2021 was $10.83M, a 16.92% increase from fiscal 2020.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-07-31 | $1.94M 10-Q · filed 2026-09-09 | $5.26M derived: sum of 4 quarters · filed 2026-09-09 |
| 2026-04-30 | $1.25M 10-Q · filed 2026-06-10 | $5.25M derived: sum of 4 quarters · filed 2026-09-09 |
| 2026-01-31 | $1.63M 10-Q · filed 2026-03-09 | $4.02M derived: sum of 4 quarters · filed 2026-09-09 |
| 2025-10-31 | $454.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-12 | $2.38M 10-K · filed 2026-01-12 |
| 2025-07-31 | $1.93M 10-Q · filed 2026-09-09 | |
| 2025-04-30 | $14.00K 10-Q · filed 2026-06-10 | |
| 2024-10-31 | -$29.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-12 | $2.96M 10-K · filed 2026-01-12 |
| 2024-07-31 | -$45.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-09-10 | |
| 2024-04-30 | $833.00K 10-Q · filed 2025-05-28 | |
| 2024-01-31 | $2.20M 10-Q · filed 2025-03-11 | |
| 2022-10-31 | $100.00M 10-K · filed 2023-01-04 | |
| 2021-10-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-01-04 | $10.83M 10-K · filed 2023-01-04 |
| 2021-07-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-09-09 | $12.23M derived: sum of 4 quarters · filed 2022-09-09 |
| 2021-04-30 | $4.88M 10-Q · filed 2022-06-10 | $17.07M derived: sum of 4 quarters · filed 2022-06-10 |
| 2021-01-31 | $5.96M 10-Q · filed 2022-03-11 | $13.47M derived: sum of 4 quarters · filed 2022-03-11 |
| 2020-10-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-04 | $9.27M 10-K · filed 2022-01-04 |
| 2020-07-31 | $4.83M 10-Q · filed 2021-09-01 | |
| 2020-04-30 | $1.28M 10-Q · filed 2021-06-10 | |
| 2020-01-31 | $1.75M 10-Q · filed 2021-03-11 | |
| 2017-10-31 | $3.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-01-11 | $3.21M 10-K · filed 2019-01-11 |
| 2017-07-31 | -$991.52K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-09-08 | |
| 2011-10-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2013-01-29 | $1.25M 10-K · filed 2013-01-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 |